LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mobile Kidney Disease Testing Device Measures Urine Albumin at POC

By LabMedica International staff writers
Posted on 06 Jul 2022
Print article
Image: A new portable medical device can monitor and enable early detection of CKD (Photo courtesy of Flinders University)
Image: A new portable medical device can monitor and enable early detection of CKD (Photo courtesy of Flinders University)

A new portable medical device for monitoring and early detection of chronic kidney disease (CKD), which affects an estimated 9% of the world’s population, has been shown to have potential to service rural and remote patients and communities with limited medical services. The affordable device can accurately measure levels of albumin in patients’ urine. Elevated albuminuria levels indicate an individual’s kidneys are not filtering blood proteins effectively.

The 3D printed medical device was designed, constructed and evaluated by researchers at Flinders University (Adelaide, Australia) and accurately measures concentrations of albumin in urine samples via an advanced specified aggregation induced emission (AIE) biosensor. In a proof-of-concept study, the platform was able to detect urinary albumin with high accuracy and low cost, making it a potential device for detecting and monitoring albuminuria levels for kidney disease.

The device is also adaptable for potential monitoring of cancers, amyloid fibrils, and other disease biomarkers. The system requires a digital camera, embedded printed circuit boards, single light source and access to the software and can be operated by anyone without the need for a clinical setting or expert diagnostic laboratory.

“A reliable, portable device to accurately measure urine albumin could be rolled out to point-of-care testing sites in the community to reduce the need for patients with chronic kidney disease to regularly visit a hospital or clinic,” said co-author Professor Karen Reynolds, Director of Flinders University’s Medical Device Research Institute and Joint Research Centre for Personal Health Technologies at Tonsley Innovation District. “It will also help early detection of kidney disease which is imperative for early intervention to slow its progression.”

Related Links:
Flinders University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more